TRAIL has been shown to be effective in eliminating cancer cells by inducing apoptosis and by fusing the ligand to a Kv10.1-specific antibody can overcome the limitations of the soluble TRAIL, like short half-life or less specificity (Hartung et al. 2011). This evidence concerns the gene TNFSF10 and cancer.